Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects

@article{Kaplan2004BloodAU,
  title={Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects},
  author={Jonathan Kaplan and Lewis R. Mandel and Richard C. Stillman and Robert W. Walker and William J. A. Vandenheuvel and J. Christian Gillin and Richard Jed Wyatt},
  journal={Psychopharmacologia},
  year={2004},
  volume={38},
  pages={239-245}
}
Psychoactive doses (0.7 mg/kg) of the hallucinogen N,N-dimethyltryptamine (DMT) were administered intramuscularly to 11 normal subjects. A gas chromatographic-mass spectrometric isotope dilution determination of DMT concentrations in whole blood and urine revealed that only a fraction of the injected dose was recovered and the blood DMT concentrations had a very similar time course o the subjectively reported “high”. 

Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects

The hallucinogenic substance N′,N′-dimethyltryptamine and its precursor N-methylryptamine were found in 24-h speciments of urine from 19 normal human subjects and the urinary excretion of both compounds was unrelated to age, sex, urinary volume, or creatinine, nor was any consistent diurnal pattern observed.

Neuropharmacology of N,N-dimethyltryptamine

eview europharmacology of N , N-dimethyltryptamine heresa

This paper reviews the current literature of both the recreational use of DMT and its potential roles as an endogenous neurotransmitter and Pharmacokinetics.

N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function

This report provides a historical overview of research concerning the endogenous hallucinogen N, N-dimethyltryptamine (DMT), focusing on data regarding its biosynthesis and metabolism in the brain

Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.

The present results show the existence in humans of alternative metabolic routes for DMT other than biotransformation by MAO and that O-demethylation plus conjugation is an important but probably not the only metabolic route for the harmala alkaloids in humans.

Dimethyltryptamine: Endogenous Role and Therapeutic Potential

While the role of endogenous DMT remains unclear, ayahuasca has promising results in anxiety, depression and substance dependence, and it is crucial to conduct further research aimed at developing new treatments for psychiatric disorders.

Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).

The synthesis of DMT is covered, as well as its pharmacology, metabolism, adverse effects, and potential use in medicine.

Chapter 15 – Tryptamines

Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases.

Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact

The toxicokinetics and toxicodynamics of the psychoactive DMT and harmala alkaloids harmine, harmaline and tetrahydroharmine, are comprehensively covered, particularly emphasizing the psychological, physiological, and toxic effects deriving from their concomitant intake.

References

SHOWING 1-10 OF 24 REFERENCES

Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man

DMT produced markedly significant mental effects including anxiety, hallucinations, and perceptual distortions and autonomic changes consisting of pupillary dilatation, increase in systolic and diastolic blood pressure, and a decrease in the kneejerk threshold.

Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients

A gas chromatographic-mass spectrometric determination of the plasma N,N-dimethyltryptamine concentration from normals and psychiatric patients revealed that within the limit of sensitivity of the

Indole(ethyl)amine N-methyltransferase in human brain.

Preliminary evidence gathered in laboratories from rats infused intraventricularly with bufotenin has suggested that this substance is at least as potent as its powerfully hallucinogenic 5-methoxy congener, and may not easily cross the blood-brain barrier.

Psychotomimetic N-Methylated Tryptamines: Formation in Brain in vivo and in vitro

An enzyme that converts tryptamine and N-methyl-tryptamine to N- methyl-and dimethyltryptamine was found to be present in rat and human brain.

Tryptamine, N,N-Dimethyltryptamine, N,N-Dimethyl-5-hydroxytryptamine and 5-Methoxytryptamine in Human Blood and Urine

5-Methoxytryptamine has been found in the urine of patients with rheumatic fever, and that in an order of magnitude of 30–210 µg/24 h, while N,N-dimethyl-5-hydroxytryptamine was still not demonstrated in blood.

Detection of Psychotomimetic N,N-Dimethylated Indoleamines in the Urine of Four Schizophrenic Patients

On the basis of their previous work indicating that tryptamine appeared in increased concentrations in the urine before and during the activation of psychotic symptoms, they suggested that under loading conditions the formation of various N,N-dimethylated indoleamines might be facilitated in the body.

A dimethyltryptamine-forming enzyme in human blood.

An enzyme capable of forming the hallucinogen dimethyltryptamine was found in human red blood cells, plasma, and platelets and was higher in psychotic subjects than in nonpsychotics and was apparently related to the presence of a dialyzable inhibitor in the normal subjects.

Dimethyltryptamin: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism

Es wird festgestellt, dass Dimethyltryptamin — bei normalen Versuchspersonen — eine dem Meskalin und dem LSD-25 ähnliche psychotische Wirkung hat. Der durch Dimethyltryptamin induzierte Zustand